Microcap Ledger Lucid Diagnostics Inc. $LUCD
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Surgical & Medical Instruments & Apparatus
- Headquarters
- New York, NY
- Fiscal year end
- December 31
- Shares outstanding
- 203,243,970 [10-Q 2026-08-12]
What the company doesAI summary of filing
Lucid Diagnostics is a commercial-stage cancer prevention diagnostics company focused on detecting esophageal precancer and cancer in patients with gastroesophageal reflux disease. The company develops and markets EsoGuard, a DNA methylation test performed on esophageal cell samples collected using EsoCheck, a non-invasive swallowable cell collection device. EsoGuard is currently marketed as a laboratory-developed test in CLIA-certified laboratories and generates revenue from commercial insurance payments and out-of-network claims. The company is pursuing Medicare coverage and FDA approval for EsoGuard and has received FDA 510(k) clearance for EsoCheck and FDA Breakthrough Device designation for EsoGuard. [10-K 2026-03-25]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $2.73M | −$25.60M | −$23.40M | $33.40M | [10-Q 2026-08-12] |
| FY ended Dec 2025 | $4.71M | −$58.01M | −$46.48M | $34.70M | [10-K 2026-03-25] |
| FY ended Dec 2024 | $4.35M | −$45.53M | −$44.14M | $22.36M | [10-K 2025-03-24] |
- Quarterly cash burn
- −$11.70M
- Cash runway Estimate
- ~8.6 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-09-30 | 114,837,637 | [10-Q 2024-11-12] |
| 2024-12-31 | 157,723,241 | [10-K 2025-03-24] |
| 2025-03-31 | 90,958,695 | [10-Q 2025-05-13] |
| 2025-06-30 | 108,411,028 | [10-Q 2025-08-12] |
| 2025-09-30 | 137,508,926 | [10-Q 2025-11-12] |
| 2026-03-23 | 176,945,972 | [10-K 2026-03-25] |
| 2026-05-11 | 203,066,783 | [10-Q 2026-05-13] |
| 2026-08-10 | 203,243,970 | [10-Q 2026-08-12] |
- Shelf registration
- S-3 filed 2025-12-05; declared effective 2026-03-26 [S-3 2025-12-05]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-05-20 | Matheis Dennis | buy | 245,000 | $1.00 | [4 2026-05-21] |
| 2026-02-20 | Aklog Lishan | grant | 2,170,000 | — | [4 2026-02-24] |
| 2026-02-20 | Matheis Dennis | grant | 123,000 | — | [4 2026-02-24] |
| 2026-02-20 | White Debra | grant | 123,000 | — | [4 2026-02-24] |
| 2026-02-20 | Sparks Ronald M | grant | 123,000 | — | [4 2026-02-24] |
| 2026-02-20 | Sokolov Jacque J | grant | 123,000 | — | [4 2026-02-24] |
| 2026-02-20 | Palumbo John R | grant | 123,000 | — | [4 2026-02-24] |
| 2026-02-20 | Lapidus Stanley | grant | 123,000 | — | [4 2026-02-24] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-22 | 8-K | Regulation FD disclosure |
| 2026-08-13 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-08-12 | 10-Q | Quarterly report |
| 2026-06-24 | 8-K | Charter, bylaws or fiscal year change; Shareholder vote results |
| 2026-05-14 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-05-13 | 10-Q | Quarterly report |
| 2026-04-30 | DEF 14A | Proxy statement |
| 2026-04-24 | 8-K | Regulation FD disclosure; Other events |
| 2026-04-23 | 424B5 | Prospectus or prospectus supplement |
| 2026-04-23 | 8-K | Material agreement entered; Regulation FD disclosure |
| 2026-04-20 | PRE 14A | Proxy statement |
| 2026-03-26 | 424B5 | Prospectus or prospectus supplement |
Alerts for $LUCD
Email me when Lucid Diagnostics Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.